rewirebio.iobenchmarks
Source

Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

41698_2026_1397_MOESM1_ESM.pdf as served by the publisher · Peer-reviewed

DOI: 10.1038/s41698-026-01397-y

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
Arriba v2.1.0 (Tamura et al. 2026)F1 (all fusions, conventional RNA-seq of cell lines)0.14 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on all fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)False negatives (all fusions, conventional RNA-seq of cell lines)677 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on all fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)False positives (all fusions, conventional RNA-seq of cell lines)9,567 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on all fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)Precision (all fusions, conventional RNA-seq of cell lines)0.08 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on all fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)Recall (all fusions, conventional RNA-seq of cell lines)0.56 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on all fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)True positives (all fusions, conventional RNA-seq of cell lines)857 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on all fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)F1 (all fusions, targeted RNA-seq of cell lines)0.30 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on all fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)False negatives (all fusions, targeted RNA-seq of cell lines)195 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on all fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)False positives (all fusions, targeted RNA-seq of cell lines)64 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on all fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)Precision (all fusions, targeted RNA-seq of cell lines)0.47 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on all fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)Recall (all fusions, targeted RNA-seq of cell lines)0.22 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on all fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)True positives (all fusions, targeted RNA-seq of cell lines)56 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on all fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)F1 (driver fusions, conventional RNA-seq of cell lines)1 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on driver fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)False negatives (driver fusions, conventional RNA-seq of cell lines)0 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on driver fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)False positives (driver fusions, conventional RNA-seq of cell lines)0 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on driver fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)Precision (driver fusions, conventional RNA-seq of cell lines)1 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on driver fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)Recall (driver fusions, conventional RNA-seq of cell lines)1 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on driver fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)True positives (driver fusions, conventional RNA-seq of cell lines)61 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)Arriba on driver fusions, conventional RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)F1 (driver fusions, targeted RNA-seq of cell lines)1 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on driver fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)False negatives (driver fusions, targeted RNA-seq of cell lines)0 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on driver fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)False positives (driver fusions, targeted RNA-seq of cell lines)0 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on driver fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)Precision (driver fusions, targeted RNA-seq of cell lines)1 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on driver fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)Recall (driver fusions, targeted RNA-seq of cell lines)1 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on driver fusions, targeted RNA-seq (Tamura et al. 2026)
Arriba v2.1.0 (Tamura et al. 2026)True positives (driver fusions, targeted RNA-seq of cell lines)24 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)Arriba on driver fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)F1 (all fusions, conventional RNA-seq of cell lines)0.01 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on all fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)False negatives (all fusions, conventional RNA-seq of cell lines)665 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on all fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)False positives (all fusions, conventional RNA-seq of cell lines)160,271 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on all fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)Precision (all fusions, conventional RNA-seq of cell lines)0.00 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on all fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)Recall (all fusions, conventional RNA-seq of cell lines)0.54 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on all fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)True positives (all fusions, conventional RNA-seq of cell lines)785 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on all fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)F1 (all fusions, targeted RNA-seq of cell lines)0.23 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on all fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)False negatives (all fusions, targeted RNA-seq of cell lines)123 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on all fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)False positives (all fusions, targeted RNA-seq of cell lines)422 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on all fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)Precision (all fusions, targeted RNA-seq of cell lines)0.16 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on all fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)Recall (all fusions, targeted RNA-seq of cell lines)0.39 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on all fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)True positives (all fusions, targeted RNA-seq of cell lines)80 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on all fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)F1 (driver fusions, conventional RNA-seq of cell lines)0.89 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on driver fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)False negatives (driver fusions, conventional RNA-seq of cell lines)12 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on driver fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)False positives (driver fusions, conventional RNA-seq of cell lines)0 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on driver fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)Precision (driver fusions, conventional RNA-seq of cell lines)1 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on driver fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)Recall (driver fusions, conventional RNA-seq of cell lines)0.80 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on driver fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)True positives (driver fusions, conventional RNA-seq of cell lines)49 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)EricScript on driver fusions, conventional RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)F1 (driver fusions, targeted RNA-seq of cell lines)0.91 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on driver fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)False negatives (driver fusions, targeted RNA-seq of cell lines)4 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on driver fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)False positives (driver fusions, targeted RNA-seq of cell lines)0 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on driver fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)Precision (driver fusions, targeted RNA-seq of cell lines)1 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on driver fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)Recall (driver fusions, targeted RNA-seq of cell lines)0.83 fractionHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on driver fusions, targeted RNA-seq (Tamura et al. 2026)
EricScript v0.5.5 (Tamura et al. 2026)True positives (driver fusions, targeted RNA-seq of cell lines)20 countHaematologic cancer cell lines, hybridisation-capture targeted RNA-seq (26 cell lines)EricScript on driver fusions, targeted RNA-seq (Tamura et al. 2026)
FusionCatcher v1.33 (Tamura et al. 2026)F1 (all fusions, conventional RNA-seq of cell lines)0.08 fractionCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)FusionCatcher on all fusions, conventional RNA-seq (Tamura et al. 2026)
FusionCatcher v1.33 (Tamura et al. 2026)False negatives (all fusions, conventional RNA-seq of cell lines)295 countCCLE haematologic malignancy cell lines, conventional RNA-seq (170 cell lines)FusionCatcher on all fusions, conventional RNA-seq (Tamura et al. 2026)

Claims

Statements this source supports, each with where in the source it was checked.

  • EricScript v0.5.5 (Tamura et al. 2026): facets.method_types: Facets: method types ["supervised_machine_learning"] (Benelli et al. 2012 section 2.6: "we trained an AdaBoost classifier"; section 2.6.4: the classifier, trained with synthetic data, gives the EricScore that ranks candidate fusions)
  • Evidence summary: tumour RNA fusion detection workflows: Summary Four comparisons join the Seraseq reference and paediatric NCH cohort evidence; values cannot be pooled across studies. Tamura et al. 2026 ran 12 short-read callers on haematologic cancer cell lines; one, Genomon, comes from a co-author's group. On 61 driver fusions in conventional RNA-seq of 170 cell lines, Arriba detected all 61 (TPR 1), FusionCatcher 0.98, STAR-Fusion 0.93, InFusion 0.43 and STARChip 0.41. On 24 driver fusions in targeted RNA-seq of 26 cell lines, Arriba again reached 1 and STAR-Fusion 0.92, InFusion 0.17 and STARChip 0. A driver fusion entered these truth sets only if at least four callers, including the one scored, found it and it had literature or RT-PCR support, so fusions that most callers miss are under-represented and these values may overstate sensitivity. Against a consensus of the other callers, the number of single-caller calls, a measure of review burden, ranged on conventional RNA-seq from 327 for TrinityFusion-D and 1,061 for STAR-Fusion (PPV 0.39) to 9,567 for Arriba (PPV 0.08), 22,445 for FusionCatcher and 695,295 for Pizzly. On nanopore long reads from 51 paediatric B-ALL samples (Lin et al. 2026), scored on the dominant fusion per sample, JAFFAL reached sensitivity 0.76, LongGF 0.70 and FusionSeeker 0.63, with precision 0.79 to 0.95; the authors' own FUSILLI reached 0.81. At about one eighth of the depth, sensitivity was 0.09 to 0.27. In an independent long-read benchmark (Dorney et al. 2026 preprint), no caller exceeded F1 0.35 on 400 simulated fusions at 100 Gb and 95% read identity: CTAT-LR-Fusion 0.35 (recall 0.28, precision 0.46), JAFFAL 0.29, Genion 0.20, FusionSeeker 0.14, GFSeeker 0.07 and LongGF 0.04. On all ONT PCR-cDNA reads of the MCF7 cell line, CTAT-LR-Fusion's calls matched 20 of 53 previously reported fusions, with 51 other calls; JAFFAL matched 19 with 38 other calls and FusionSeeker 11 with 359. The other calls mix real fusions missing from the literature list and false calls. On the Huh7 cell line, pooling six long-read callers per long-read platform and three short-read callers for Illumina, PacBio Kinnex recovered 20 of 34 previously reported fusions, ONT PCR-cDNA 17 and Illumina 15. Against karyotyping, FISH and RT-PCR in 101 adult and paediatric acute leukaemia patients (Kim et al. 2026), an Arriba workflow with manual review detected 40 of 48 conventionally detected fusions (sensitivity 83.3%) and called fusions in 21.4% of 56 conventionally negative results; these count against specificity, although the authors describe several as well-known recurrent fusions and confirmed one by RT-PCR and Sanger sequencing. These are cell lines, simulations and leukaemia samples: no linked comparison covers solid-tumour specimens, FFPE tissue or novel-fusion discovery, only Kim et al. score against orthogonal clinical assays, none reports interval estimates, and none establishes clinical performance. (amp-oncology-rna-20261007-source-pmc8642973: Seraseq and NCH results; rna-fusion-20261009-source-tamura2026-supplementary: Supplementary Tables 3 and 5; rna-fusion-20261009-source-tamura2026: Methods and Author contributions; rna-fusion-20261009-source-lin2026: Tables 3 and 6, Results; rna-fusion-longread-20261011-source-dorney2026: see claims.csv of its batch; rna-fusion-longread-20261011-source-dorney2026-repository: see claims.csv of its batch; rna-fusion-leukaemia-20261011-source-kim2025: see claims.csv of its batch)
  • Relevance of All fusions, conventional RNA-seq of haematologic cell lines, consensus truth (Tamura et al. 2026 Supplementary Table 3) to "Select a tumour RNA fusion-detection workflow": Assessed by All fusions, conventional RNA-seq of haematologic cell lines, consensus truth (Tamura et al. 2026 Supplementary Table 3) (rna-fusion-20261009-source-tamura2026-supplementary: Supplementary Table 3, 'Conventional RNA-seq of cell lines'; rna-fusion-20261009-source-tamura2026: Methods 'Comparison of detection algorithms' paragraph 1; Results 'Comparative evaluation of detection algorithms for passenger and driver gene fusions using conventional RNA-seq data'; Author contributions; reference 25)
  • Relevance of All fusions, targeted RNA-seq of haematologic cell lines, consensus truth (Tamura et al. 2026 Supplementary Table 3) to "Select a tumour RNA fusion-detection workflow": Assessed by All fusions, targeted RNA-seq of haematologic cell lines, consensus truth (Tamura et al. 2026 Supplementary Table 3) (rna-fusion-20261009-source-tamura2026-supplementary: Supplementary Table 3, 'Targeted RNA-seq of cell lines'; rna-fusion-20261009-source-tamura2026: Methods 'Comparison of detection algorithms' paragraph 1; Results 'Comparative evaluation of detection algorithms for passenger and driver gene fusions using conventional RNA-seq data'; Author contributions; reference 25)
  • Relevance of Driver fusions, conventional RNA-seq of haematologic cell lines, validated truth (Tamura et al. 2026 Supplementary Table 5) to "Select a tumour RNA fusion-detection workflow": Assessed by Driver fusions, conventional RNA-seq of haematologic cell lines, validated truth (Tamura et al. 2026 Supplementary Table 5) (rna-fusion-20261009-source-tamura2026-supplementary: Supplementary Table 5, 'Conventional RNA-seq of cell lines'; rna-fusion-20261009-source-tamura2026: Methods 'Comparison of detection algorithms' paragraph 2; Results 'Limiting analysis to driver gene fusions substantially alters the performance of detection algorithms' and 'Driver gene fusion detection using targeted RNA-seq'; Author contributions; reference 25)
  • Relevance of Driver fusions, targeted RNA-seq of haematologic cell lines, validated truth (Tamura et al. 2026 Supplementary Table 5) to "Select a tumour RNA fusion-detection workflow": Assessed by Driver fusions, targeted RNA-seq of haematologic cell lines, validated truth (Tamura et al. 2026 Supplementary Table 5) (rna-fusion-20261009-source-tamura2026-supplementary: Supplementary Table 5, 'Targeted RNA-seq of cell lines'; rna-fusion-20261009-source-tamura2026: Methods 'Comparison of detection algorithms' paragraph 2; Results 'Limiting analysis to driver gene fusions substantially alters the performance of detection algorithms' and 'Driver gene fusion detection using targeted RNA-seq'; Author contributions; reference 25)

Models, benchmarks and other records

Configurations (12)

Protocols (4)

Datasets (2)

Evaluations (48)

Use cases (1)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

17 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-adc15377fab2
Property and statementOriginal source and locationReview and provenance
Artifact SHA-256
f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact url
https://static-content.springer.com/esm/art%3A10.1038%2Fs41698-026-01397-y/MediaObjects/41698_2026_1397_MOESM1_ESM.pdf
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Doi
10.1038/s41698-026-01397-y
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Licence
CC-BY-NC-ND-4.0
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Media type
application/pdf
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Publication status
peer_reviewed
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieved at
2026-10-09T20:37:37Z
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Url
https://doi.org/10.1038/s41698-026-01397-y
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.url

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Version
41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.version

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Description
Supplementary PDF with per-algorithm detection statistics.
Source metadata
Tamura et al. 2026, Supplementary Information (Supplementary Tables 1-12)

Original source ↗

No field-specific location recorded

Version: 41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
Retrieved: 2026-10-09T20:37:37Z

catalogued

No individual claim review recorded

Audit details

Field: description

Source artifact SHA-256: f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-adc15377fab2 · Record review: source checked

Supplementary PDF with per-algorithm detection statistics.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: rna-fusion-20261009-source-tamura2026-supplementary

areas
rna-transcriptomes
contexts
clinical_research
url
https://doi.org/10.1038/s41698-026-01397-y
artifact url
https://static-content.springer.com/esm/art%3A10.1038%2Fs41698-026-01397-y/MediaObjects/41698_2026_1397_MOESM1_ESM.pdf
version
41698_2026_1397_MOESM1_ESM.pdf as served by the publisher
retrieved at
2026-10-09T20:37:37Z
artifact sha256
f18ada098fd03b0842c63a8ab9d13002e1876b006243e42c640a118ea3ab3275
doi
10.1038/s41698-026-01397-y
publication status
peer_reviewed
licence
CC-BY-NC-ND-4.0
media type
application/pdf
Related records

    Suggest a correction